Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | PPARD | Q03181 | 9/20 | 0.50 |
| ▸ | PPARG | P37231 | 4/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435132 | 0.87 | ALDH1A1 (0.51) | ALDH1A1PTGDR2POLBSMN1; SMN2 | |
| SCHEMBL19398382 | 0.87 | ALDH1A1 (0.51) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL14787928 | 0.85 | ALDH1A1 (0.63) | ALDH1A1PTGDR2POLBSMN1; SMN2 | |
| SCHEMBL2281472 | 0.84 | ALDH1A1 (0.55) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL13850149 | 0.84 | ALDH1A1 (0.56) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL28590760 | 0.83 | ALDH1A1 (0.72) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL5693207 | 0.83 | ALDH1A1 (0.54) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL29956334 | 0.83 | POLB (0.65) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL6536289 | 0.83 | POLB (0.74) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL5246469 | 0.83 | POLB (0.65) | ALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2021-11-25 | — | — | US | disclosed |
| EP-3253754-B1 | 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | KANCERA AB (SE) | 2021-03-31 | — | — | EP | disclosed |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2020-11-12 | — | — | US | disclosed |
| US-10550113-B2 | 2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | KANCERA AB (SE) | 2020-02-04 | — | — | US | disclosed |
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2018-04-19 | — | — | US | disclosed |
| US-20180002329-A1 | 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | KANCERA AB (SE) | 2018-01-04 | — | — | US | disclosed |
| WO-2016124553-A1 | 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | KANCERA AB (SE) | 2016-08-11 | — | — | WO | disclosed |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2016-04-21 | — | — | US | disclosed |
| US-9199990-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2015-12-01 | — | — | US | disclosed |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (US) | 2015-03-12 | — | — | US | disclosed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
| EP-1513526-B1 | PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORP (US) | 2007-11-07 | — | — | EP | disclosed |
| US-7199239-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-20060074111-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-04-06 | — | — | US | disclosed |
| EP-1392674-B1 | FURAN AND THIOPHENE DERIVATIVES THAT ACTIVATE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-10 | — | — | EP | disclosed |
| EP-1513795-A2 | PROPIONIC ACID DERIVATIVES AND THEIR USE AS HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-16 | — | — | EP | disclosed |
| EP-1392674-A1 | FURAN AND THIOPHENE DERIVATIVES THAT ACTIVATE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GLAXO GROUP LIMITED (GB) | 2004-03-03 | — | — | EP | disclosed |
| WO-2004000762-A2 | PROPIONIC ACID DERIVATIVES AND THEIR USE AS HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2002092590-A1 | FURAN AND THIOPHENE DERIVATIVES THAT ACTIVATE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GLAXO GROUP LIMITED (GB) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885PTGDR2 1574/4885POLB 2324/4885 |
| US-10550113-B2 | 2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | ROR1, RORB, RORA | ALDH1A1 317/4885PTGDR2 2525/4885POLB 2765/4885 |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885PTGDR2 1574/4885POLB 2324/4885 |
| US-20060074111-A1 | Chemical compounds | HDAC3, HAT1, H1-3 | ALDH1A1 980/4885PTGDR2 4016/4885POLB 3614/4885 |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885PTGDR2 1574/4885POLB 2324/4885 |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885PTGDR2 1574/4885POLB 2324/4885 |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885PTGDR2 1574/4885POLB 2324/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | ALDH1A1 1784/4885PTGDR2 1323/4885POLB 3140/4885 |
| US-20180002329-A1 | 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | ROR1, RORB, RORA | ALDH1A1 317/4885PTGDR2 2525/4885POLB 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.